Alert icon

To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action.
This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm.
To view information about this, please visit the FAQ. If you have any further questions, please contact us.

Back to the List
Type(s) of Cancer
Pancreatic
Study Phase
Phase 3
Study Completion Date
November 2012
NCT01124786Uploaded 05-17-2017
Available for Download
PDS UID: Pancrea_ClovisO_2010_186
A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
Provider Information
Provider Data DescriptionSee outcome measures
SponsorClovis Oncology
Data ProviderClovis
Partial set or SubsetN/A
Patients in dataset232
# of Patients Control118
# of Patients Experimental118
DOIhttps://doi.org/10.34949/q15p-en76
CDISC StandardADS
Study ArmsBoth comparator and experimental arm data
Clinical Trials.gov Information
Brief SummaryThe purpose of this study is to determine whether CO-1.01 is safe and effective in the treatment of patients with metastatic pancreatic cancer and low hENT1 expression compared with gemcitabine.
ConditionsMetastatic Pancreatic Adenocarcinoma
Intervention TypeDrug: CO-1.01
Drug: Gemcitabine
Drug(s)Drug: CO-1.01
Drug: Gemcitabine
Total Enrolled367
RandomizationRandomized
Blinding MethodNone (Open Label)
Arms InterventionCO-1.01 - Experimental
gemcitabine - Active Comparator
Secondary IDNA
PubMed (PMID)NA
Collaborator(s)NA
Region(s)United States
Argentina
Australia
Belgium
Brazil
Canada
France
Germany
Italy
Netherlands
Norway
Russian Federation
Sweden
Ukraine
United Kingdom
Age RangeMinimum Age: 18 Years
Maximum Age: N/A
Files:
PROTOCOLProtocol_CO-101-001_Amend2 20110314 final.pdf
CRFCVSDVPAN-ADVPAN aCRF 13-Sep-2010_2.pdf
DATA DICTIONARYdefine.pdf
DATA (ACTIVE ARM)SAP CO-101-001 Amendment 1 03May2012.docx
DATA (ACTIVE ARM)DataSphere.zip
© 2021 Project Data Sphere
All rights reserved
Privacy PolicyTerms of Use